Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03995901
NCT03995901TerminatedPhase 3

A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors

Talaris Therapeutics Inc.33 sites in 1 country15 target enrollmentStarted: October 25, 2019Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Status
Terminated
Enrollment
15
Locations
33
Primary Endpoint
Proportion of FCR001 recipients who are free from immunosuppression (IS), without biopsy proven acute rejection (BPAR) at 24 months post-transplant
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

A randomized controlled study to evaluate the safety, efficacy, and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.

Detailed Description

The purpose of this randomized (2:1) controlled study is to evaluate the safety, efficacy and overall benefit of FCR001 cell therapy in first or second de novo living donor renal transplantation relative to a standard-of-care control immunosuppression regimen of antibody induction, tacrolimus, mycophenolate, and corticosteroids.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Recipient age ≥18 years.
  • •Donor age ≥18 and ≤60 years at time of signing informed consent.
  • •Recipients of a first or second living donor kidney transplant
  • •Donor willing to undergo mobilization, apheresis and 12-month safety follow-up and meet all local standard eligibility criteria to donate stem cells for allogeneic transplantation.
  • •Recipient meets all local standard eligibility criteria for allogeneic stem cell transplant.
  • •Donors must be deemed eligible as per the requirements of 21CFR
  • •Main Recipient and Donor

Exclusion Criteria

  • •Recipient and donor who are identical twins.
  • •Recipient or donor with history of malignancy or premalignant syndrome (e.g., myelodysplastic syndrome, monoclonal gammopathy of renal significance [MGRS], monoclonal gammopathy of unknown significance [MGUS]) of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • •Recipient or donor with known bone marrow aplasia.
  • •Main Recipient-only Exclusion Criteria:
  • •Multi-organ or stem cell transplant recipient.
  • •Calculated panel reactive antibodies >80%.
  • •Recipient is blood type ABO incompatible with donor.
  • •Presence of donor-specific antibodies (DSA) (positive result) at any time pre-transplant.
  • •Recipient who is human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) positive.
  • •Recipient with any baseline condition requiring or anticipated will require chronic or intermittent use of systemic steroids or other IS (eg, autoimmune disease, asthma) throughout the course of the study.
  • •Recipient with a BMI < 18 or > 35 kg/m
  • •Recipient requiring systemic anticoagulation, (eg, for hyper-coagulation disorders, deep vein thrombosis, atrial fibrillation) that cannot be temporarily interrupted which would preclude renal biopsy.
  • •Main Donor-only Exclusion Criteria:
  • •Biologically unrelated (i.e., no genetic relationship) female donor transplant to male recipient.

Outcomes

Primary Outcomes

Proportion of FCR001 recipients who are free from immunosuppression (IS), without biopsy proven acute rejection (BPAR) at 24 months post-transplant

Time Frame: 24 months post-transplant

Free from IS is defined as not taking any immunosuppression medications and not having to take immunosuppression medications since their withdrawal. Biopsy proven acute rejection is defined as Grade ≥1A according to the Banff 2017 Classification of Antibody-Medicated Rejection and T Cell-Mediated Rejection in Renal Allografts (Haas et al 2018).

Secondary Outcomes

  • Allograft function (eGFR by MDRD4) and change in eGFR from Month 1 to Month 24, 36, and Month 60, by treatment(Month 1 (post-transplant) to Month 24, 36, and Month 60)
  • Slope and difference in slope of estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease (MDRD4) over time to Month 24, 36, and 60, by treatment(Month 24, 36, and 60)
  • Incidence of de novo donor-specific antibodies(Months 12, 24, 36 and 60)
  • Incidence or worsening of abnormal histologic findings of cellular or antibody-mediated chronic rejection, chronic glomerulopathy, tubular atrophy and interstitial fibrosis, C4d, calcineurin inhibitor induced damage, disease recurrence, BK nephropathy(Months 12, 24, 36 and 60)
  • Incidence of renal replacement therapy by treatment group(Months 12, 24, 36 and 60)
  • Change in renal function by Modification of Diet in Renal Disease (MDRD4) from post-transplant baseline (Month 1) to Month 24 in FCR001 recipients(24 months post-transplant)
  • Allograft function (eGFR) and change in renal allograft function from Month 1 to Months 24, 36 and 60 by treatment group, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula(Month 1 (post transplant) to Month 24, 36, and Month 60)
  • Time to the event for the composite of BPAR, graft loss, death or lost to follow-up and for each component, by treatment group(Month 1 (post transplant) to Month 6, 12, 24, 36, and 60)
  • Incidence of composite endpoint of BPAR, graft loss, or death and lost to follow-up, by treatment group(Months 12, 24, 36 and 60)
  • Incidence of BPAR and treated BPAR by severity, type, and steroid-resistance, by treatment group(Months 12, 24, 36 and 60)
  • Incidence of BK viremia, viruria, infection, and nephropathy by treatment(Months 12, 24, 36 and 60)
  • Subject quality of life according to End-Stage Renal Disease Symptom Checklist (ESRD-SCL) will be analyzed descriptively by treatment group(Months 12, 24, 36 and 60)
  • Incidence and duration of hospitalization and readmission, according to type of ward/unit(Months 12, 24, 36 and 60)
  • To describe the incidence and severity of AEs (including infections) and SAEs among FCR001 donors(Month 24, 36, and 60)
  • Incidence of acute rejection, death, renal graft loss, and lost to follow-up between FCR001 recipients who did not achieve durable chimerism or the ability to wean or remain off immunosuppression vs. the control arm(Month 24, 36, and 60)
  • Proportion of FCR001 recipients free from IS, without BPAR, at Month 36 and 60(Month 36 and 60 post transplant)
  • iBox predicted allograft survival(Months 12 and 24 post-transplant)
  • The incidence of autologous infusions in FCR001 recipients(Month 6, 12, 24, 36, and 60)
  • The correlation of donor chimerism with freedom from IS)in FCR001 recipients will be described(Month 6, 12, 24, 36, and 60)
  • Incidence of composite endpoint of BPAR, graft loss or death, by treatment group(Months 12, 24, 36 and 60)
  • Incidence of acute rejection(Months 12, 24, 36 and 60)
  • Incidence of BPAR or eGFR <50 mL/min by treatment group(Months 12, 24, 36 and 60)
  • The incidence of engraftment syndrome in FCR001 recipients(Month 6, 12, 24, 36, and 60)
  • The time to neutrophil and platelet recovery in FCR001 recipients(Month 6, 12, 24, 36, and 60)
  • The incidence of donor chimerism and level of chimerism by study visit in FCR001 recipients will be described(Month 6, 12, 24, 36, and 60)
  • Categorical distribution of eGFR according to chronic kidney disease CKD staging classification by treatment(Months 12, 24, 36 and 60)
  • Incidence of the adverse events of special interest (proteinuria, neurotoxicity, anemia, diabetes, hypertension, dyslipidemia, opportunistic infections, major adverse cardiovascular events, and malignancies(Months 12, 24, 36 and 60)
  • Graft and patient survival and eGFR in FCR001 recipients who are only transiently chimeric(Month 24, 36, and 60)
  • Incidence and severity of adverse events (AEs; including infections), serious adverse events (SAEs) and AEs leading to study and/or regimen discontinuation(Months 12, 24, 36 and 60)
  • Urinary protein and albumin excretion, estimated by urinary protein/creatinine and urinary albumin/creatinine ratios by treatment group(Months 12, 24, 36 and 60)
  • Subject quality of life according to 36-Item Short Form Health Survey (SF-36) will be analyzed descriptively by treatment group(Months 12, 24, 36 and 60)
  • The incidence of blood component transfusions in FCR001 recipients(Month 6, 12, 24, 36, and 60)
  • The incidence of acute and chronic Graft versus Host Disease (GvHD) in FCR001 recipients will be described(Month 6, 12, 24, 36, and 60)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (33)

Loading locations...

Similar Trials

Withdrawn
Phase 2
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney RecipientsKidney Transplantation
NCT01649388Talaris Therapeutics Inc.
Not yet recruiting
Phase 1
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLB-cell Acute Lymphoblastic Leukemia
NCT04595162Peking University Third Hospital12
Unknown
Phase 3
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerBreast Cancer
NCT05755048Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.314
Recruiting
Phase 1
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's LymphomaNon-Hodgkin's Lymphoma
NCT06206902Shanghai Simnova Biotechnology Co.,Ltd.55
Recruiting
Phase 1
F01 in the Treatment of Autoimmune DiseasesAutoimmune Diseases
NCT06208280RenJi Hospital20